These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 12695731

  • 41. A comparison of placebo responders and nonresponders in subgroups of depressive disorder.
    Bialik RJ, Ravindran AV, Bakish D, Lapierre YD.
    J Psychiatry Neurosci; 1995 Jul; 20(4):265-70. PubMed ID: 7647079
    [Abstract] [Full Text] [Related]

  • 42. Efficacy of nomifensine in different depressive syndromes.
    Overall JE.
    J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):85-8. PubMed ID: 6370983
    [Abstract] [Full Text] [Related]

  • 43. Psychiatry should not become hostage to placebo: an alternative interpretation of antidepressant-placebo differences in the treatment response in depression.
    Rihmer Z, Dome P, Baldwin DS, Gonda X.
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):782-6. PubMed ID: 22497852
    [Abstract] [Full Text] [Related]

  • 44. Antidepressant treatment of tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit.
    Dobie RA, Sakai CS, Sullivan MD, Katon WJ, Russo J.
    Am J Otol; 1993 Jan; 14(1):18-23. PubMed ID: 8424470
    [Abstract] [Full Text] [Related]

  • 45. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews.
    Khan A, Faucett J, Brown WA.
    J Psychiatr Res; 2014 Apr; 51():88-92. PubMed ID: 24477068
    [Abstract] [Full Text] [Related]

  • 46. [Placebo effect in the drug therapy of depression].
    Hougaard E, Nielsen T, Zachariae B.
    Ugeskr Laeger; 2000 Apr 17; 162(16):2314-7. PubMed ID: 10827560
    [Abstract] [Full Text] [Related]

  • 47. [Pharmacologic treatment of bulimia].
    Corcos M, Flament M, Atger F, Jeammet P.
    Encephale; 1996 Apr 17; 22(2):133-42. PubMed ID: 8706623
    [Abstract] [Full Text] [Related]

  • 48. [Clinical double blind comparison of diclofensine and placebo in geriatric patients with depressive syndromes].
    Jansen W, Brückner GW, Henauer S, Omer LM.
    Pharmacopsychiatria; 1982 Nov 17; 15(6):205-9. PubMed ID: 6760217
    [Abstract] [Full Text] [Related]

  • 49. Placebo responses in randomized trials of antiepileptic drugs.
    Guekht AB, Korczyn AD, Bondareva IB, Gusev EI.
    Epilepsy Behav; 2010 Jan 17; 17(1):64-9. PubMed ID: 19919904
    [Abstract] [Full Text] [Related]

  • 50. [Delay of the antidepressant effect: clinical studies].
    Escande M, Gentil V, Frexinos M.
    Encephale; 1995 Mar 17; 21 Spec No 2():3-8. PubMed ID: 7588175
    [Abstract] [Full Text] [Related]

  • 51. Who should receive antidepressants: suggestions from placebo treatment.
    Khan A, Brown WA.
    Psychopharmacol Bull; 1991 Mar 17; 27(3):271-4. PubMed ID: 1775597
    [Abstract] [Full Text] [Related]

  • 52. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.
    Khan A, Khan SR, Shankles EB, Polissar NL.
    Int Clin Psychopharmacol; 2002 Nov 17; 17(6):281-5. PubMed ID: 12409681
    [Abstract] [Full Text] [Related]

  • 53. Antidepressant response and plasma concentrations of bupropion.
    Preskorn SH.
    J Clin Psychiatry; 1983 May 17; 44(5 Pt 2):137-9. PubMed ID: 6406443
    [Abstract] [Full Text] [Related]

  • 54. Placebo protects subjects from nonresponse: a paradox of power.
    Leon AC.
    Arch Gen Psychiatry; 2000 Apr 17; 57(4):329-30. PubMed ID: 10768693
    [No Abstract] [Full Text] [Related]

  • 55. Effect size as a measure of symptom-specific drug change in clinical trials.
    Leon AC, Shear MK, Portera L, Klerman GL.
    Psychopharmacol Bull; 1993 Apr 17; 29(2):163-7. PubMed ID: 8290660
    [Abstract] [Full Text] [Related]

  • 56. The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials.
    Mallinckrodt CH, Prucka WR.
    Clin Pharmacol Ther; 2010 Nov 17; 88(5):592-4. PubMed ID: 20959845
    [Abstract] [Full Text] [Related]

  • 57. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.
    Khan A, Warner HA, Brown WA.
    Arch Gen Psychiatry; 2000 Apr 17; 57(4):311-7. PubMed ID: 10768687
    [Abstract] [Full Text] [Related]

  • 58. [Target symptoms in the utilization of antidepressants].
    Tatarelli R, Girardi P, Vella G.
    Encephale; 1984 Apr 17; 10(1):29-32. PubMed ID: 6376067
    [Abstract] [Full Text] [Related]

  • 59. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis.
    Khan A, Brodhead AE, Kolts RL.
    Int Clin Psychopharmacol; 2004 May 17; 19(3):157-60. PubMed ID: 15107658
    [Abstract] [Full Text] [Related]

  • 60. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration.
    Borges S, Chen YF, Laughren TP, Temple R, Patel HD, David PA, Mathis M, Unger E, Yang P, Khin NA.
    J Clin Psychiatry; 2014 Mar 17; 75(3):205-14. PubMed ID: 24717376
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.